Keymed Biosciences Inc. Stock
Stocks
2162
KYG5252B1023
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.05 HKD | +1.91% |
|
+11.39% | +19.83% |
| 06-05 | Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close | MT |
| 06-04 | Lakefront Biotherapeutics, Gilead Complete Ouro Acquisition for $1.68 Billion Upfront | MT |
| Market Cap | 16.37B 18.87B 2.41B 2.11B 1.94B 1.82B 3.41B 227B 3.48B 23.37B 9.04B 112B 9.04B 8.84B 389B | P/E 2026 * |
32.1x | P/E 2027 * | 151x |
|---|---|---|---|---|---|
| Enterprise Value | 15.56B 17.94B 2.29B 2.01B 1.85B 1.73B 3.25B 216B 3.31B 22.23B 8.6B 107B 8.59B 8.4B 370B | EV / Sales 2026 * |
6.47x | EV / Sales 2027 * | 7.02x |
| Free-Float |
70.26% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.91% | ||
| 1 week | +11.39% | ||
| Current month | +3.64% | ||
| 1 month | +7.65% | ||
| 3 months | +5.78% | ||
| 6 months | +18.17% | ||
| Current year | +19.83% |
| 1 week | 54.75 |  | 66.8 |
| 1 month | 52.6 | | 66.8 |
| Current year | 44.66 | | 81.85 |
| 1 year | 44.45 | | 81.85 |
| 3 years | 26.6 | | 81.85 |
| 5 years | 16.9 | | 82.85 |
| 10 years | 16.9 | | 82.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bo Chen
CEO | Chief Executive Officer | 52 | 2018-04-22 |
Changyu Wang
PRN | Corporate Officer/Principal | 61 | 2021-03-02 |
Pak Yu Tam
SEC | Corporate Secretary | - | 2022-03-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Bo Chen
CHM | Chairman | 52 | 2018-04-22 |
Changyu Wang
BRD | Director/Board Member | 61 | 2021-03-02 |
Gang Xu
BRD | Director/Board Member | 52 | 2018-06-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25-06-12 | Moonshot Holdings Ltd.
| Other | Company | 21,600,000 | 7.7216% | |
| 25-06-10 | Moonshot Holdings Ltd.
| Other | Company | 18,800,000 | 6.7206% | |
| 23-09-14 | Moonshot Holdings Ltd.
| Other | Company | 114,500 | 0.0409% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.91% | +11.39% | +38.49% | +56.22% | 2.41B | |
| +0.33% | +1.37% | +63.66% | +126.38% | 55.63B | |
| +0.82% | +15.05% | +79.52% | +85.53% | 52.25B | |
| +1.36% | +0.36% | -14.52% | -13.83% | 23.07B | |
| -1.04% | +7.91% | +3.91% | +417.68% | 22.41B | |
| -0.18% | +7.20% | +31.37% | -13.62% | 17.32B | |
| -1.10% | +4.00% | +29.97% | -33.36% | 15.94B | |
| +2.89% | +5.51% | +25.42% | +186.30% | 13.77B | |
| -3.35% | +8.96% | +134.32% | +289.59% | 13.47B | |
| +1.31% | +0.53% | +27.83% | - | 12.43B | |
| Average | +0.30% | +5.44% | +42.00% | +122.32% | 22.87B | |
| Weighted average by Cap. | +0.28% | +5.20% | +48.39% | +121.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.41B 2.77B 354M 310M 286M 268M 502M 33.36B 512M 3.43B 1.33B 16.49B 1.33B 1.3B 57.17B | 2.16B 2.49B 317M 278M 256M 240M 450M 29.89B 459M 3.08B 1.19B 14.77B 1.19B 1.16B 51.23B |
| Net income | 295M 341M 43.44M 38.09M 35.11M 32.87M 61.63M 4.1B 62.91M 422M 163M 2.03B 163M 160M 7.02B | 44.14M 50.88M 6.49M 5.69M 5.24M 4.91M 9.21M 612M 9.4M 63.03M 24.39M 303M 24.36M 23.83M 1.05B |
| Net Debt | -804M -927M -118M -104M -95.58M -89.48M -168M -11.16B -171M -1.15B -445M -5.51B -444M -434M -19.12B | -1.23B -1.42B -181M -158M -146M -137M -256M -17.04B -262M -1.76B -679M -8.42B -678M -664M -29.21B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-26 | HK$64.05 | +1.91% | 3,626,008 |
| 26-06-25 | HK$62.85 | +3.03% | 4,836,828 |
| 26-06-24 | HK$61.00 | +3.39% | 3,956,500 |
| 26-06-23 | HK$59.00 | +4.06% | 4,047,500 |
| 26-06-22 | HK$56.70 | -1.39% | 2,082,800 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2162 Stock
Select your edition
All financial news and data tailored to specific country editions
